Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma (PCYC-04753)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pharmacyclics
ClinicalTrials.gov Identifier:
NCT00849654
First received: February 20, 2009
Last updated: May 21, 2013
Last verified: May 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2012
  Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
No publications provided by Pharmacyclics

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):